Jacobs Levy Equity Management Inc. Reduces Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Jacobs Levy Equity Management Inc. has significantly reduced its stake in Ironwood Pharmaceuticals by 56.4%, selling over 2 million shares in the first quarter, leaving it with a total of approximately 1.58 million shares valued at around $2.32 million.
• Brokerages have shown mixed sentiments on Ironwood Pharmaceuticals, with Zacks Research downgrading the stock from "strong buy" to "hold" while Wall Street Zen upgraded it to "strong buy," resulting in a consensus rating of "Hold" with an average target price of $4.94.
• Ironwood Pharmaceuticals reported a quarterly revenue of $85.24 million, significantly above consensus estimates of $62.02 million, along with earnings per share of $0.14, beating estimates by $0.16.

Jacobs Levy Equity Management Inc. lowered its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 56.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,580,320 shares of the biotechnology company's stock after selling 2,042,706 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.98% of Ironwood Pharmaceuticals worth $2,323,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Armistice Capital LLC boosted its position in Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after acquiring an additional 4,232,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Ironwood Pharmaceuticals by 33.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,647,015 shares of the biotechnology company's stock worth $3,891,000 after purchasing an additional 663,775 shares during the period. AQR Capital Management LLC raised its stake in Ironwood Pharmaceuticals by 535.8% during the first quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company's stock worth $3,710,000 after purchasing an additional 2,126,889 shares during the period. Northern Trust Corp raised its stake in Ironwood Pharmaceuticals by 7.9% during the fourth quarter. Northern Trust Corp now owns 1,625,110 shares of the biotechnology company's stock worth $7,199,000 after purchasing an additional 118,962 shares during the period. Finally, Deutsche Bank AG raised its stake in Ironwood Pharmaceuticals by 47.4% during the fourth quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock worth $6,944,000 after purchasing an additional 504,336 shares during the period.

Ironwood Pharmaceuticals Stock Up 5.6%

Shares of IRWD stock traded up $0.07 during mid-day trading on Friday, reaching $1.31. The company's stock had a trading volume of 816,432 shares, compared to its average volume of 1,247,972. The company's 50 day simple moving average is $0.98 and its 200-day simple moving average is $0.97. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $5.13. The firm has a market capitalization of $212.78 million, a PE ratio of -26.19 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million for the quarter, compared to the consensus estimate of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IRWD shares. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 5th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $4.94.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.